New Strategies for Obesity Management: Risk Stratification & Long-term Weight Control

Houston, TX

Vertical Tabs

Overview

Obesity is a disease, requiring a concerted therapeutic focus according to the "medical" model.  The advent of new medications fill the previous void in the lack of effective options for medical therapy.  The patient treatment goal is to achieve the degree of weight loss sufficient to achieve targets for improving complications and reducing risk.  Employing risk stratification methods and appropriate patient selection for various treatment options and intensity of treatment options can optimize risk/benefit ratio and patient outcomes.  This educational activity will present these integral themes and address all relevant aspects of obesity epidemiology, pathophysiology, complications, and treatment.

Target Audience

This activity is intended for MD's, DO's, NP's, RN's, PA's, CDE's, Pharmacists and other interested health care providers.

 

LEARNER BILL OF RIGHTS 

 

The American Association of Clinical Endocrinologists (AACE) recognizes that you are a life-long learner who has chosen to engage in continuing medical education to identify or fill a gap in knowledge, skill or performance.  As part of AACE’s duty to you as a learner, you have the right to expect that your continuing medical education experience with AACE includes:

 

CONTENT that:

  • Promotes improvements or quality in healthcare;
  • Is valid, reliable and accurate;
  • Offers balanced presentations that are free of commercial bias for or against a product/service;
  • Is vetted through a process that resolves any conflicts of interests of planners, teachers or authors;
  • Is driven and based on learning needs, not commercial interests;
  • Addresses the stated objectives or purpose; and
  • Is evaluated for its effectiveness in meeting the identified educational need.

 

A LEARNING ENVIRONMENT that:

  • Supports learners’ ability to meet their individual needs;
  • Respects and attends to any special needs of the learners;
  • Respects the diversity of groups of learners; and
  • Is free of promotional, commercial and/or sales activities.

 

DISCLOSURE of:

  • Relevant financial relationships planners, teachers and authors have with commercial interests related to the content of the activity; and
  • Commercial support (funding or in-kind resources) of the activity.

 

 

Agenda

Saturday, September 21, 2013

7:00 am - 12:00 pm CST

New Strategies for Obesity Management: Risk Stratification & Long-term Weight Control

  

Time   Agenda Item
7:00am - 8:00am             Registration & Continental Breakfast
8:00am - 8:10am   Welcome Remarks & Program Overview
8:10am - 8:30am   Epidemiology of Obesity
8:30am - 9:00am   Complications of Obesity
9:00am - 9:30am   Mechanisms of Obesity
9:30am - 9:45am   Break
9:45am - 10:00am   Evaluation of the Obese Patient
10:00am - 10:20am   Lifestyle Interventions
10:20am - 10:40am   Pharmacotherapy for Weight Loss
10:40am - 11:00am   Surgical Treatment of Obesity
11:00am - 11:30am   Weight Loss in Type 2 Diabetes
11:30am - 11:50am     Panel Discussion and Questions & Answers
11:50am - 12:00pm     Concluding Remarks
12:00pm   Adjourn

 

 

 

 

 

 

 

 

 

 

 

*Agenda Subject to Change

 

The activity is co-provided/co-sponsored by the American Association of Clinical Endocrinologists and the Postgraduate Institute for Medicine.

                

 
Faculty

*Alan J. Garber, MD, PhD, FACE - Chair

Professor, Departments of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology

Baylor College of Medicine, Houston, TX

 

*W. Timothy Garvey, MD

Professor and Chair, Department of Nutrition Sciences

University of Alabama at Birmingham (UAB)

Director, UAB Diabetes Research Training Center, Birmingham, AL

 

Priscilla Hollander, MD, PhD

Medical Director for Diabetes

Baylor Hospital System

Baylor Endocrine Center

Dallas, Texas

 

Janet B. McGill, MD, FACE

Professor of Medicine

Washington University School of Medicine

St. Louis, MO

 

*Denotes member of both steering committee and faculty.

Educational Objectives

At the conclusion of this educational activity, the participant should be able to:

  • List the pathological features of obesity that qualify it as a disease rather than a behavioral choice
  • Identify the body systems affected by obesity and list at least 6 obesity complications
  • Discuss the relationship between fat deposition and cardiometabolic risk
  • Describe at least 2 methods for stratifying obese patients according to their risk of complications
  • Explain the components of effective lifestyle intervention for obesity and how patients can be encouraged to adopt these changes
  • Compare the benefits and limitations of pharmacologic therapy for obesity
  • Identify weight loss goals appropriate to patients’ individual risk profiles and design treatment interventions aimed at achieving those goals
  • Implement  treatment interventions aimed at achieving weight loss goal
  • Provide accurate and appropriate counsel as part of the treatment team
  • Provide appropriate care and counsel for patients and their families

 

Steering/Program Committee

*Alan J. Garber, MD, PhD, FACE - Chair

Professor, Departments of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology

Baylor College of Medicine, Houston, TX

 

*W. Timothy Garvey, MD

Professor and Chair, Department of Nutrition Sciences

University of Alabama at Birmingham (UAB)

Director, UAB Diabetes Research Training Center, Birmingham, AL

 

George Grunberger, MD, FACP, FACE

Chairman, Grunberger Diabetes Institute

Clinical Professor, Department of Internal Medicine Center for Molecular Medicine & Genetics

Wayne State University School of Medicine, Bloomfield Hills, MI

 

*Janet B. McGill, MD, FACE

Professor of Medicine

Washington University School of Medicine

St. Louis, MO

 

Jeffrey I. Mechanick, MD, FACP, FACE, FACN, ECNU

Clinical Professor of Medicine

Director, Metabolic Support

Division of Endocrinology, Diabetes & Bone Disease

Icahn School of Medicine at Mount Sinai

New York, NY

 

*Denotes individual is both a member of the Program Committee and the Faculty.

Disclosure

Faculty Disclosures

*Dr. Alan Garber reports that he has received Advisory Board, consultant,and Speaker’s Bureau’s fees from Merck & Co., Inc., Novo Nordisk A/S, and VIVUS Inc.; Advisory Board fees from Halozyme Therapeutics; Advisory Board and Speaker’s Bureau fees from Janssen Pharmaceuticals, Inc.; Advisory Board and consultant fees from Takeda Pharmaceuticals North America, Inc.; consultant and Speaker’s Bureau fees from Santarus Inc.; consultant fees from Tethys Bioscience and Viking Therapeutics; and Speaker’s Bureau fees from Eisai Co, Ltd. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Garber has an identified conflict of interest and it has been resolved accordingly.  He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

 

*Dr. Timothy Garvey reports that he has received research support and speaker honoraria from Merck & Co., Inc.; research support from Amylin Pharmaceuticals, Inc., and Weight Watchers International, Inc.; and Advisory Board honoraria from Alkermes, Daiichi-Sanko Company, Limited, Janssen Pharmaceuticals, Inc., LipoScience Inc., Tethys Bioscience, and VIVUS. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Garvey has an identified conflict of interest, and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

 

Dr. Priscilla Hollander reports that she has received Advisory Board honoraria from Merck & Co., Inc., Novo Nordisk A/S, and sanofi-aventis U.S. LLC. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Hollander has an identified conflict of interest and it has been resolved accordingly.  She has been required by the AACE CME Accreditation Committee to base her presentation and recommendations on the best available, preferably published evidence/information.

 

*Dr. Janet McGill reports that she has received grant support for her role as Washington University Principal Investigator from Andromeda Biotech Ltd., Bristol-Myers Squibb/AstraZeneca, Mannkind Corporation, Novartis AG, Takeda Pharmaceuticals North America, Inc. and sanofi-aventis U.S. LLC; speaker/advisor honoraria from Boehringer Ingelheim GmbHI/Eli Lilly and Company and Merck & Company, Inc.; advisor honoraria from Abbott Laboratories, Halozyme Therapeutics, Janssen Pharmaceuticals Inc., and Novo Nordisk  A/S; and consultant honoraria from Reata Pharmaceuticals Inc. and Vitae Pharmaceuticals.  Dr. McGill has no identified conflicts of interest.

 

Steering Committee Disclosures

Dr. George Grunberger reports that he has received speaker honoraria and research support for his role as Investigator from Amylin Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, and Valeritas, Inc., speaker honoraria from Amarin Corp. and Santarus Inc., and research support for his role as Investigator from GlaxoSmithKline plc and Janssen Pharmaceuticals, Inc.  Dr. Garvey has no identified conflicts of interest.

 

Dr. Jeffrey Mechanick reports that he has received lecture/program development honoraria from Abbott Laboratories. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Mechanick has an identified conflict of interest and it has been resolved accordingly.  He has been required by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

 

*Denotes individual is also a member of the Program Committee.

 

Postgraduate Institute for Medicine Disclosures

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Corporate Support

 This is activity is supported by an educational grant from VIVUS, Inc.

Location

Crowne Plaza Houston - Downtown

1700 Smith Street

Houston, TX 77002

http://www.cpdowntown.com/

Physician Credit

This activity has been approved for AMA PRA Category 1 Credit™

 

Nursing Credit

Credit Designation

This educational activity for 3.7 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Postgraduate Institute for Medicine is approved by the California Board of Registered Nursing, Provider Number 13485 for 3.7 contact hours.

There is no fee for this educational activity. A statement of credit will be issued only upon receipt of a completed online evaluation and a certificate will be made available immediately.

For information about ACPE and ANCC accreditation, please contact Postgraduate Institute for Medicine at (303) 799-1930 or information@pimed.com.

Pharmacist Credit

 

Accreditation Statement

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

 

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 3.75 contact hour(s) (0.375 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0809-9999-13-308-L01-P)

Type of Activity: Application

Upon receipt of a completed online activity evaluation form, transcript information will be available at www.mycmemonitor.net immediately.

For information about ACPE and ANCC accreditation, please contact Postgraduate Institute for Medicine at (303) 799-1930 or information@pimed.com.

Dietitian Credit

DIETICIAN CREDIT

This activity has been approved by the Commission on Dietetic Registration for 3.75 CPEUs

 

 

Registration Fees

There is no fee to attend this activity.

 

AACE Membership is not required to attend this program.

 

However, we do ask that you register by clicking the next tab and completing the registration form.

Register
Program Fee
There is no registration fee to attend this meeting. We do request that you pre-register by completing this form. AACE Membership is NOT required to attend this program.
Registration Type
Contact Information
Cancellation Policy
AACE reserves the right to cancel this course based on enrollment or conditions beyond our control. In the case of program cancellation, each pre-registrant will be notified by phone and/or email. AACE is not responsible for any costs incurred due to program cancellation, such as airline or hotel penalties.
E-mail Disclaimer
By entering your email address, you agree that your email address can be used for future correspondence from the American Association of Clinical Endocrinologists. This information would include, but is not limited to certifications, program information and future advertisements.
Finish Registration
A Printed Syllabus will NOT be distributed for this activity.
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.